Metropolitan Life Insurance Company (MetLife)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,885
| Closed | -$202K | – | 2543 |
|
|
2023
Q1 | $202K | Sell |
1,885
-275
| -13% | -$29.5K | 0.01% | 661 |
|
|
2022
Q4 | $238K | Buy |
2,160
+368
| +21% | +$40.5K | 0.01% | 646 |
|
|
2022
Q3 | $106K | Hold |
1,792
| – | – | 0.01% | 983 |
|
|
2022
Q2 | $50.6K | Hold |
1,792
| – | – | ﹤0.01% | 1502 |
|
|
2022
Q1 | $67.7K | Sell |
1,792
-6,532
| -78% | -$247K | ﹤0.01% | 1424 |
|
|
2021
Q4 | $329K | Buy |
8,324
+4,609
| +124% | +$182K | ﹤0.01% | 1693 |
|
|
2021
Q3 | $88.1K | Buy |
+3,715
| New | +$88.1K | ﹤0.01% | 2598 |
|